alexa Adenosine in the Bone Marrow Myeloma Niche: Immune Checkpoint and Key Player in the Progression of Myeloma Disease | OMICS International
ISSN: 2576-1471
Journal of Cell Signaling

Like us on:

Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Adenosine in the Bone Marrow Myeloma Niche: Immune Checkpoint and Key Player in the Progression of Myeloma Disease

Horenstein AL1*, Quarona V1, Morandi F2, Chillemi A2 and Malavasi F1

1Department of Medical Sciences, Laboratory of Immunogenetics, University of Torino, Italy

2Laboratory of Oncology, Istituto Giannina Gaslini, Genova, Italy

*Corresponding Author:
Horenstein AL
Department of Medical Sciences
Laboratory of Immunogenetics
University of Torino, Italy
E-mail: [email protected]

Received date: February 14, 2017; Accepted date: March 15, 2017; Published date: March 27, 2017

Citation: Horenstein AL, Quarona V, Morandi F, Chillemi A, Malavasi F (2017) Adenosine in the Bone Marrow Myeloma Niche: Immune Checkpoint and Key Player in the Progression of Myeloma Disease. J Cell Signal 2:141.

Copyright: © 2017 Horenstein AL, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Journal of Cell Signaling


The tumor microenvironment is rich extracellular mono- and dinucleotides (ATP, NAD+), which are metabolized by cell surface ecto enzymes to produce increased local concentrations of adenosine (Ado), a nucleoside involved the control of inflammation and immune responses [1]. A recent study by our group demonstrated that adenosinergic pathways contribute to customize the immune homeostasis of multiple myeloma (MM) [2]. A plasma cell malignancy, MM prevalently develops and expands with bone marrow (BM) niches [3]. Malignant plasma cells at all stages of the disease overexpress CD38 [4], a molecule with widespread tissue distribution and complex functions not yet fully elucidated. CD38 is a 45-kDa type II (or III) trans membrane glycoprote expressed by several immune and non-immune cell types, and it plays a dual role as a receptor and as an ectoenzyme [5]. As a nucleotide-metabolizing ectoenzyme, CD38 catalyzes at neutral pH the extracellular conversion of a dinucleotide of adenine (NAD+) to cADPR and ADPR. At acidic pH, CD38 can also catalyze the exchange of the nicotinamide group of NADP+ with nicotinic acid and produce NAADP+ and ADPRP.

All of the final products are basic regulators of calcium signaling [6]. The initial disassembly of NAD+ is followed by adenosinergic activity, provided that CD38 is operating the presence of other ectoenzymes (ectonucleotide pyrophosphatase/phosphodiesterase CD203a and 5’- nucleotidase CD73). These findings point to the existence of an alternative axis for extracellular production of the immunosuppressive Ado. Such a pathway would be able to flank and, some instances, to bypass the canonical pathway based on the conversion of ATP by the ecto-nucleoside triphosphate diphosphohydrolase CD39 [7,8]. These coordinated networks may be hijacked by the tumour for its own purposes.

These observations are relevant to myeloma homeostasis the BM. For energy production and the synthesis of nucleotides and other macromolecules, malignant plasma cells favour glycolysis over oxidative phosphorylation (the Warburg effect), thus sacrificing efficiency for speed. This metabolic shift is hallmarked by hypoxic conditions, and leads to a decrease ATP concentrations and a concurrent increase NAD+ levels to susta high-rate glycolysis. this context, extracellular Ado may originates and be released from tumor cells depleted of ATP, or it may derive from extracellular ATP and NAD+ leaked from damaged tumor tissues.

As a consequence, Ado may assume the role of a local hormone, adjusting cellular metabolism either via low or high affinity specific receptors expressed by normal and tumor cells [5]. Evidence for this is our finding that CD56bright CD16+ NK cells produce Ado through a CD38-mediated pathway [9]. The functional relevance is that these NK cells operate as activated immune effector/regulatory cells inhibiting autologous CD4+ T cell proliferation. This strategy of immune escape has already been observed: melanoma cells produce Ado through a CD38/CD203a/CD73 pathway and suppress CD4+ T cell proliferation [10].

These actions can ultimately lead to immune suppression. Ado is thus seen to contribute to the failure of immune surveillance cancer. It is reasonable to hypothesize that a similar metabolic strategy is deployed to silence immune effectors during the progression of MM from indolent monoclonal gammopathies to symptomatic overt disease [2]. Now clinical application is a therapeutic anti-CD38 antibody used to deplete immune-regulatory CD38+ cell populations; this is accompanied by expansion of CD4+ T-helper cells and CD8+ cytotoxic T-cells MM [11].

As expected, elevated levels of extracellular Ado were detected plasma obtained from the myeloma BM niche for diagnostic purposes [2]. We showed that NAD+ with the BM niche is able to activate a discontinuous (i.e., multicellular) pathway for Ado production that relies upon CD38, CD203a and CD73 (or TRAP) ectonucleotidases, depending on the environmental pH. Observed variations of the Ado concentrations BM plasma aspirates were likely due to interactions taking place between myeloma and other cells lining the niche (Figure 1).


Figure 1: Pooled data portraying a hypothetical model according to which human malignant myeloma under aerobic conditions directly supports the production of Ado for the generation of a tolerant BM niche. Ado is obtained from NAD+ which undergoes reaction through a multicellular cha of ecto nucleotidases (CD38*, CD203a, and CD73 or TRAP** depending on pH status). According to this view, NAD+ is decomposed into products that flow the BM plasma fluid with the myeloma niche, accumulating variable amounts of Ado. Most of the Ado is eventually taken up by purinergic cell receptors expressed by bone cells or immune cells inside the niche.The outcome is either a block of the effectiveness of immune cells (Teff, NK) that are capable of destroying tumor cells or that increase the number of regulatory T-cells (Tregs) and mesenchymal derived stromal cells (MDSC), which suppress immune cells from responding to the tumor (not shown). *CD38 expressed by myeloma cells are revealed by specific fluorescent antibodies. **TRAP: Tartrate resistant acid phosphatase.

The results of a pilot study revealed a parallel between Ado levels and disease progression, and patients with symptomatic MM usually have high Ado. This is reflected statistically the International Staging System (ISS) for MM [2]. While these observations may only be correlative and a reflection of the tumor burden, Ado levels the BM plasma may prove to be a useful marker of myeloma progression. Another aspect of the dynamics of available anti-CD38 antibodies for MM therapy is the role of polarization and release of micro vesicles (MV). These plasma membrane structures are known to express several molecules clustered lipid domains [12]. The MV deriving from MM are peculiar that they are rich CD38, CD203a and CD73 and can therefore generate Ado [13]. Meanwhile, the adenosinergic pathways have become new immune checkpoint targets for improving the efficacy of immunotherapies designed with the aim of re-engaging the depressed immune system [14,15].


Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Article Usage

  • Total views: 537
  • [From(publication date):
    March-2017 - May 27, 2018]
  • Breakdown by view type
  • HTML page views : 480
  • PDF downloads : 57

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals


[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
Leave Your Message 24x7